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ABSTRACT 
Persistent corneal epithelial defects (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-
14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal 
layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision 
loss. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still 
be quite challenging. It is important to treat the underlying causative condition, which may include an infection, limbal stem 
cell deficiency, or diabetes, in order to facilitate wound healing. Standard treatments, such as bandage contact lenses (BCLs) 
and artificial tears (ATs), aim to provide barrier protection to the epithelial layer. Recently-developed medical treatments can 
target the re-epithelialization process by facilitating access to growth factors and anti-inflammatory agents, and novel surgical 
techniques can provide re-innervation to the cornea. PEDs should be treated within 7-10 days to avoid secondary 
complications. These interventions, along with a step-wise approach to management, can be useful in patients with PEDs that 
are refractory to standard medical treatment. In this review, we discuss the epidemiology, etiology, diagnosis, current and 
novel management, and prognosis of persistent epithelial defects. 
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INTRODUCTION
The cornea is the transparent, outermost layer of the eye 
that uniformly refracts the majority of light that enters 
the eye onto the lens and is essential for ideal vision. The 
multi-layered corneal epithelium acts as a protective 
barrier to infectious agents via tight junctions between 
neighboring cells, and it maintains its smooth optical 
surface by constantly regenerating cells in the basal cell 
layer [1, 2]. Disruptions in this protective layer can render 
the eye susceptible to infection, stromal ulceration, 
perforation, scarring, and decreased visual acuity [3-5]. 
The tear film, composed of lipid, aqueous, and mucin 
layers, also helps maintain corneal transparency and 
smoothness. For this reason, artificial tears are used as 
one of the initial therapies of ocular surface disorders to 
restore this film. Abrasions and corneal epithelial defects 
are some of the most common ocular pathologies that 
present to ophthalmologists. Persistent corneal epithelial 
defects (PEDs or PCEDs) result from the failure of rapid 
re-epithelialization and closure within 10-14 days after a 
corneal injury, even with standard supportive treatment 
[4, 5]. If left untreated, PEDs can result in significant 
complications, including infection and vision loss. This 
review of the current literature will encompass the 
epidemiology, etiology, diagnosis, current and novel 
management, and prognosis of persistent epithelial 
defects.  
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Epithelial Wound Healing 
The self-renewing corneal epithelium consists of 
stratified squamous cells and is separated into three 
layers: the outer two to three cell layers comprise the 
superficial layer, the middle two to three cell layers 
create the wing layer, and the innermost cell layer is 
the basal cell layer. The epithelial basement 
membrane resides between the basal epithelial cells 
and the stroma. The limbus, located at the periphery 
of the cornea, contains both epithelial stem cells, 
which proliferate into the basal epithelium, and basal 
cells. Epidermal growth factor (EGF) mediates the 
proliferation and migration process, as it promotes 
synthesis of nucleic acids in epithelial cells and stromal 
fibroblasts as well as stimulates the production of 
extracellular matrix protein, fibronectin, by epithelial 
cells. As basal cells migrate towards the central 
surface of the cornea, they gradually lose their 
proliferative properties and eventually undergo 
apoptosis and are desquamated into the tear film [4]. 
Several other growth factors, matrix and degradation 
proteins, and receptors are involved in the corneal 
healing process, making healing after an epithelial 
defect very complex. For example, metalloproteinases, 
cathepsins, and plasminogen are regulated by growth 
factors and play an important role in healing and 
tissue remodeling by modifying adhesion interactions 
and the extracellular matrix [6]. During corneal 
epithelial wound healing, inflammatory cytokines, 
such as tumor necrosis factor alpha (TNF-α) and 
interleukin-1 (IL-1), are released in response to 
damage to the epithelium. Keratocytes respond to IL-1 
and produce growth factors, such as hepatocyte 
growth factor (HGF) and keratocytes growth factor 
(KGF), which influence the migration and proliferation 
of epithelial cells. Insulin-like growth factors (IGFs) and 
transforming growth factor beta (TGF-β) regulate 
differentiation and growth of stromal keratocytes and 
epithelial cells. Platelet-derived growth factors 
(PDGFs) regulate migration and proliferation of 
keratocytes, and thymosin-β4 promotes re-
epithelialization and mediates epithelial migration 
during wound healing. Nerve growth factor (NGF) 
plays a vital role in trophic support, corneal sensation, 
and maintaining the tear film [4, 6]. Any alteration to 
this highly regulated process can result in abnormally 
slow healing.  
In normal conditions after an injury to the cornea, the 
epithelial layer undergoes an active repair process 
over 7-14 days, which involves a highly regulated 
cascade of growth factors, cellular signaling, 
proliferation, migration, extracellular matrix 
remodeling, and eventual quiescence or apoptosis [2, 
4, 6]. Fig. 1 and 2 present the growth factors and 
inflammatory mediators involved in the normal 
corneal epithelial wound healing process. Only after 
re-epithelialization can the stroma adhere to the 
regenerated epithelial layer via hemidesmosomes 
anchoring to fibrils; therefore, if the epithelium cannot 
attach to the stroma, tissue defects can develop. If the 
underlying basement membrane remains intact, the 
epithelial healing process takes around 7 days to 
develop, regenerate, and adhere to the underlying 
basement membrane. However, if the underlying 
stromal layer is also affected in addition to the 
basement membrane, the epithelial layer will 
regenerate over the lesion and attach to the 
recovering stromal layer after around eight weeks. 
PEDs commonly extend into the stromal layer, causing 
stromal melting, secondary ulceration, and stromal 
scarring [4]. An insult to the cornea resulting in an 
acute epithelial defect is a lesion that usually heals 
over the 7-14-day time frame, whereas a persistent 
epithelial defect is unable to close within this normal 
interval. Fig. 3 models a persistent epithelial defect 
compared to the normal tissue layers of the cornea. 
 
Figure 1: Growth Factors and Inflammatory Mediators Involved in the 
Epithelial Wound Healing Process. In the Case of Injury to the Cornea, 
Interleukin 1 (IL-1) is secreted by the Damaged Epithelial Cells, 
Causing some Keratocytes to Undergo Apoptosis and some to 
Proliferate into Activated Keratocytes. Epithelial Cells will also Secrete 
Transforming Growth Factor-beta (TGF-β) in Response to Destruction 
of the Basement Membrane and Results in Myofibroblast 
transformation. Growth Factors Insulin-like Growth Factor (IGF), 
Insulin, Epidermal Growth Factor (EGF), platelet-Derived Growth 
Factor (PDGF), Keratinocyte Growth Factor (KGF), and Hepatocyte 
Growth Factor (HGF) Play Important Roles in Corneal Wound Healing. 
EGF, IGF and Insulin Regulate Epithelial Growth and Stromal 
Keratocyte Activation. KGF and HGF are produced by Keratocytes to 
influence Migration and Proliferation of Epithelial Cells. PDGF 
Regulates Epithelial Proliferation and Keratocyte Function [2, 6]. 
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METHODS 
To find information on PED and current treatments, a 
literature search was performed using the following 
sources: PubMed, Google Scholar, Embase, and Scopus 
with the keywords “persistent epithelial defect”, 
“persistent corneal epithelial defect”, “PED”, “treatment 
of persistent epithelial defects”, “neurotrophic persistent 
corneal epithelial defect”, “non-healing corneal epithelial 
defect”, “corneal re-epithelialization”, “corneal wound 
healing”, and “epithelial abrasion”. Articles describing 
the epidemiology, etiology, diagnosis, current and novel 
management, and prognosis of PEDs were systematically 
reviewed. Reference lists detailed in each paper were 
examined to identify additional pertinent articles. There 
were no language restrictions. Publications were drawn 
between the dates of 1980-2019.  
Epidemiology 
The incidence of PED is unknown. However, studies 
based on the etiology of the disease estimate that the 
annual incidence of PED is less than 200,000 cases in the 
U.S., thus classifying PED as a relatively rare disease [7]. 
For example, ocular herpes simplex can result in PED, 
epithelial and stromal keratitis, scarring, tissue 
destruction, neovascularization, and glaucoma. The 
incidence of ocular herpes simplex in the U.S. is an 
estimated 20.7 per 100,000 person-years. Additionally, in 
the U.S., the incidence of PED following a corneal 
transplant is around 7,558 cases per year, and the 
incidence of PED after a diabetic vitrectomy is around 
2,480-5,257 cases per year. Diabetic keratopathy is 
estimated to occur in 47-64% of diabetic patients and 
increases the risk of acquiring epithelial defects [7].  
A recent study on the epidemiology of epithelial defects 
after penetrating keratoplasty surgeries in patients with 
infectious keratitis reveals that factors that increase the 
risk for postoperative epithelial defects include male sex, 
> 60 years, graft diameter > 9 mm, bacterial or viral 
etiology, comorbid systemic diseases, such as rheumatic 
diseases and cancer therapy [8]. Additionally, another 
study showed that among a cohort of 53 children 
exposed to mechanical ventilation, 25% developed a 
corneal epithelial defect [9]. In addition, precautions and 
early management should be considered for patients 
who undergo pars plana vitrectomy due to the high 
incidence of postoperative PED [10]. 
 
 
Figure 2: Normal Epithelial Wound Healing Process [11, 12]. 
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Figure 3: Depiction of a Persistent Epithelial Defect (PED). Note that in the Schematic of a PED, there is Loss of Part of the Anterior Stroma. Additionally, 
the Epithelial Cells are Unable to Migrate Centrally, Resulting in Epithelial Cell Growth on the Edges of the PED Lesion. The Basement Membrane has 
also been Eroded and Thinned. IL-1: Interleukin 1; TNF-α: Tumor Necrosis Factor; MMPs: Matrix Metallopeptidases; ECM: Extracellular Matrix. 
 
Etiology
The normal corneal wound healing process can be 
disrupted from defective epithelial adhesion, limbal 
stem cell deficiency, surface trauma, medications, 
infections, and several other etiologies discussed below. 
The pathophysiology of PED involves proliferation of 
myofibroblasts and a resulting disordered extracellular 
matrix, producing an opacity in the cornea [5].  
Defective Epithelial Adhesion 
Basal epithelial cells produce and adhere to the 
basement membrane by forming hemidesmosomes and 
fibril connections. Defective epithelial adhesion or a 
deficient basement membrane can cause an increased 
risk for persistent corneal epithelial defects [4]. 
Recurrent corneal erosions can result in an 
overproduction of matrix metalloproteinases (MMPs) 
that disrupt the basement membrane and destroy fibril 
connections between the epithelium and basement 
membrane, leading to an increased risk for a PED. 
Epithelial basement membrane dystrophies (EBMD) can 
cause irregular extra basement membrane layers that 
are created and extend into the epithelium, resulting in 
a defective basement membrane and secondary 
adhesions. Toxic keratopathy can result in PEDs, as 
topical anesthetics can disrupt the migration of 
epithelial cells and interfere with hemidesmosome 
adhesion mechanisms between the epithelium and 
basement membrane. Degeneration of the cornea in 
Salzmann’s nodular degeneration, band keratopathy, 
bullous keratopathy, vitamin A deficiency, and scarring 
can result in PEDs due to abnormal formation of the 
basement membrane and defective adhesion 
mechanisms [4]. 
Limbal Stem Cell Deficiency 
Epithelial cell migration and corneal epithelial stem cells 
in the limbus are crucial to regenerate the tissue after 
an insult to the corneal epithelium. Therefore, limbal 
stem cell deficiency (LSCD) often results in the inability 
of epithelial regeneration, stromal melting, scarring, 
persistent epithelial defects, corneal 
conjunctivalization, and neovascularization [13, 14]. 
One of the common causes of severe limbal stem cell 
deficiency is an alkali-induced chemical injury from lye, 
household cleaning solutions, and fertilizers, for 
example [15]. 
Inflammation 
Cytokines, such as tumor necrosis factor alpha (TNF-α) 
and interleukin-1 (IL-1), mediate inflammation and 
induce production of growth factors by keratocytes that 
drive proliferation and migration of epithelial cells. 
These growth factors also promote the synthesis of 
proteases, such as MMPs and chemotactic factors that 
stimulate stromal remodeling and if in excess, stromal 
melting. Several inflammatory conditions can lead to 
PED due to disruption of corneal wound healing by 
over-activity of TNF-α, IL-1, and other inflammatory 
cytokines. These conditions include keratoconjunctivitis 
sicca, rosacea, infectious keratitis, autoimmune 
diseases, Sjögren’s syndrome, mucous membrane 
pemphigoid, Stevens-Johnson syndrome, graft versus  
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host disease, peripheral ulcerative keratitis, Mooren’s 
ulcer, and rheumatoid arthritis [4]. 
Neurotrophic 
The cornea is one of the most densely-innervated 
tissues in the human body and receives neural 
sensation and neurotrophic factors from the 
ophthalmic branch of the trigeminal nerve [16]. 
Neurotrophic persistent corneal epithelial defects are 
caused by local or systemic damage to the trigeminal 
nerve, resulting in decreased corneal sensation. The 
loss of corneal innervation causes degeneration of 
tissue, with the epithelium being most susceptible to 
damage, resulting in epithelial defects and poor 
corneal healing [16, 17]. Denervation causes 
decreased metabolism and proliferation of epithelial 
cells, resulting in subsequent epithelial layer 
dysfunction. Additionally, decreased blink rate, tear 
production, and Meibomian gland excretion can 
further exacerbate epithelial defects. Causes of 
damage to corneal nerves include diabetes mellitus, 
severe dry eye syndrome, current or past herpetic 
keratitis, anesthetic abuse, and traumatic or 
postoperative nerve damage [4, 16].  
Mechanical 
Recurrent abrasions and insults to the ocular surface can 
result in depletion of epithelial stem cells from a constant 
need to regenerate the epithelial layer. Thus, if the 
extent of loss of epithelial cells exceeds the healing 
properties of limbal stem cells, a PED can form. These 
mechanical injuries include exposure keratopathy from 
lagophthalmos, entropion or ectropion, trichiasis, 
blepharospasm, pseudomembranes or tarsal scars, and 
trachoma [4]. Severe dry eye disease can foster 
development of a PED, due to ocular surface mucin 
deficiency in the tear film from Stevens-Johnson 
syndrome or lacrimal gland damage in Sjögren’s 
syndrome, for example [7]. Additionally, a herpetic 
infection, dry eye disease, or inflammatory condition can 
cause mechanical irritation of the cornea from abnormal 
eyelids or even denervation of the cornea [4]. Corneal 
burns from chemical or thermal injuries can result in PED 
if the burn extends deep into the epithelium and stromal 
layer, resulting in an inability of re-epithelialization [18]. 
Idiopathic and Hereditary Disorders 
Aniridia and corneal, stromal, and epithelial basement 
membrane dystrophies can cause PEDs, due to a 
deficiency in limbal stem cells and abnormal basement 
membrane adhesion mechanisms, respectively [4]. Table 
1 highlights some of the common etiologies of PED. 
 
Table 1: Etiologies of Defective Corneal Epithelial Wound Healing [4].  
Underlying Etiology  
Examples of causative 
diseases 
Mechanism 
Defective epithelial 
adhesion  
Recurrent corneal erosions 
Epithelial basement 
membrane dystrophies 
(EBMD) 
Toxic keratopathy 
Salzmann’s nodular 
degeneration 
Band keratopathy 
Bullous keratopathy 
Vitamin A deficiency 
Scarring and trauma 
Defective epithelial 
adhesion, deficient or 
abnormal basement 
membrane, 
overproduction of matrix 
metalloproteinases 
(MMPs), disruption of 
migration of epithelial 
cells 
Limbal stem cell 
deficiency 
Limbal stem cell deficiency 
(LSCD) 
Alkali-induced chemical 
injury 
Trauma 
Deficiency of limbal stem 
cells 
Inflammation  
Keratoconjunctivitis sicca 
Rosacea 
Infectious keratitis 
Autoimmune diseases 
Sjögren’s syndrome 
Mucous membrane 
pemphigoid 
Stevens-Johnson syndrome 
Graft vs. host disease 
Peripheral ulcerative 
keratitis 
Mooren’s ulcer 
Rheumatoid arthritis 
Over-activity of cytokines 
(TNF- α and IL-1), 
production of growth 
factors by keratocytes, 
proliferation and 
migration of epithelial 
cells, stromal remodeling 
Neurotrophic  
Diabetes mellitus 
Severe dry eye syndrome 
Current or past herpetic 
keratitis 
Anesthetic abuse 
Traumatic or postoperative 
nerve damage 
Local or systemic damage 
to trigeminal nerve, loss 
of corneal innervation 
Mechanical  
Lagophthalmos 
Entropion or ectropion 
Trichiasis 
Blepharospasm 
Pseudomembranes or 
tarsal scars 
Trachoma 
Severe dry eye disease 
(mucin deficiency) 
Sjögren’s syndrome 
(lacrimal gland damage) 
Herpetic infection 
Chemical or thermal 
injuries resulting in corneal 
burns 
Recurrent abrasions can 
result in depletion of 
epithelial stem cells, dry 
or inflammatory ocular 
surface, corneal erosions 
from eyelid abnormalities 
Idiopathic and 
hereditary 
disorders  
Aniridia 
Corneal, stromal and 
epithelial basement 
membrane dystrophies 
Deficiency in limbal stem 
cells 
Abnormal basement 
membrane adhesion 
TNF-α: Tumor Necrosis Factor Alpha; IL-1: Interleukin 
 
Diagnosis and Clinical Presentation 
Evaluating a PED involves fluorescein instillation to 
monitor the size, location, and depth of the defect [19]. 
In deeper PEDs, it takes a longer time for the 
fluorescein to absorb into the epithelium and stroma. A 
thorough physical exam should reveal findings such as 
inflammation in the anterior chamber, eyelid 
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abnormalities, or decreased sensation of the cornea, 
such as in the case of a neurotrophic PED.   
Distinguishing an epithelial defect from a PED can be 
determined by the length of time the epithelial defect 
closes after injury to the cornea; an epithelial defect 
will recover after 7-10 days, whereas a PED will not heal 
even after 2 weeks and is usually refractory to standard 
therapies and supportive care [4]. A comprehensive 
patient history should be taken to highlight any 
possibilities of a previous herpetic infection, diabetes, 
immune system disorders, pain, or blurry vision.  
Although rare, LSCD commonly results in PED and may 
be clinically diagnosed by stippled late fluorescein 
staining and detection of corneal opacities, decreased 
vision, photophobia, unstable tear film, and superficial 
vascularization. PED along with LSCD may later present 
with scarring, ulceration, stromal neovascularization or 
perforation [20]. 
Treatment of Persistent Epithelial Defects of the 
Cornea 
The consequences of an untreated PED include 
increased risk of infection, anterior stromal scarring, 
melting, neovascularization, ulceration, perforation, 
and significant vision loss [7]. Therefore, PEDs should be 
treated within 7-10 days to avoid secondary 
complications. Treatment should also increase in 
aggressiveness 10 days after diagnosis of a PED in hopes 
of preventing stromal fibrosis [5]. Clinicians should treat 
all cases of PEDs, including those with a partially healed 
epithelial layer.  
Management of PED is complex and involves several 
treatment options depending on its etiology. Healthy 
corneas may rapidly recover from an epithelial defect 
with supportive care; however, corneal healing may be 
hindered by disrupted cellular signaling from several 
etiologies that cause a PED, such as trauma, infection, 
severe dry eye disease, herpetic infections, diabetes 
mellitus, neurotrophic keratopathies, and 
complications after penetrating keratoplasties [3, 21]. 
PEDs occur if the cornea is unable to heal an epithelial 
defect within two weeks with standard supportive 
treatment; thus, the lesion exposes the underlying 
stromal layer to further damage, or infection [4]. 
Ocular epithelial diseases are particularly challenging 
to manage because treatment requires an 
understanding of the disease process and the 
mechanism of various medications and procedures 
discussed in this section. The goal of treatment is to 
provide protection and favorable conditions for the 
differentiated epithelial cells to migrate, proliferate, 
and regenerate the normal epithelial layer. Due to the 
complex nature of the disease, patients with PED must 
be thoroughly examined multiple times a week, or 
even daily, to ensure the effectiveness of the 
treatment course. Refer to Table 2 for a stepwise 
approach for the management of PED. 
 
 
Table 2: Stepwise Approach for the Management of Persistent Corneal Epithelial Defects 
Current Standard Management Treatment of Refractory Cases Novel treatments and therapies 
in development 
1. Treat underlying condition (i.e. diabetic keratopathies 
treated with optimal diabetes management; limbal 
stem cell deficiencies treated with limbal stem cell 
transplants; immunosuppression in Stevens-Johnson 
syndrome, graft vs. host disease, and Sjogren’s 
syndrome)  
2. Consider iatrogenic causes (i.e. benzalkonium chloride, 
topical aminoglycosides, and vancomycin drops may 
disrupt epithelialization)  
3. Aggressive lubrication with preservative-free artificial 
tears (ATs) and ocular ointments  
4. Punctal plug  
5. Bandage soft contact lenses (BCL) and/or pressure 
patching, although pressure patching may be less 
effective than BCLs 
6. Debridement, tarsorrhaphy, administration of 
botulinum toxin A, cyanoacrylates glue  
7. Tetracyclines, prophylactic topical antibiotics and 
steroids (however, corticosteroids may cause stromal 
melting)  
8. Refer to treatments of refractory cases  
Medical: 
Autologous serum eye drops  
Whole blood derived products (i.e. umbilical 
cord blood serum and platelet-rich fibrin 
tears) 
Scleral contact lenses, prosthetic 
replacement of the ocular surface 
ecosystem (PROSE) 
 
Surgical: 
Amniotic membrane grafting or transplant 
(AMT) with fibrin-glue or sutured 
underneath bandage contact lenses (BCL) 
Corneal epithelial stem cell transplantation  
Boston Keratoprosthesis (KPro) implantation  
Phototherapeutic keratectomy (PTK) 
 
Medical: 
Topical fibronectin  
Topical thymosin beta 4 (Tβ4), 
topical fibronectin-derived 
peptide (PHSRN)  
Nexagon  
Topical Epidermal growth factor 
(EGF) 
Topical insulin-like growth factor-
1 (IGF-1), topical insulin 
Human growth hormone (HGH) 
Albumin eye drops (AED)  
Matrix regenerating agent, 
ReGeneraTing Agent (RGTA) 
Amniotic membrane extract eye 
drops (AMEED) 
Oxervate (Cenergermin-bkbj), 
recombinant human nerve 
growth factor (rhNGF) 
Surgical:  
Corneal neurotization  
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Current Standard Management
In approaching treatment of a PED, the first step is to 
consider the possible etiology of the disease along with 
its clinical presentation. For example, neurotrophic 
cornea can be treated with topical nerve growth factor; 
diabetic keratopathies with optimal diabetes 
management; herpetic keratitis with antiviral treatment 
and corticosteroids; and LSCD with limbal stem cell 
transplants [5]. 
The current standard management of PEDs includes a 
stepwise strategy, starting with conservative 
management and progressing to medical or surgical 
treatments if refractory. This includes lubrication, 
bandage soft contact lenses, punctal plugs, 
debridement, and tarsorrhaphy. Initially, aggressive 
lubrication every 1-2 hours with preservative-free 
artificial tears and ocular ointments are applied to the 
eye [3]. Iatrogenic causes of a PED must also be 
considered before proceeding to therapies after 
applying artificial tears and ointments. If the patient is 
concurrently using medications that may disrupt the 
corneal epithelium, such as benzalkonium chloride, 
topical aminoglycosides (i.e., gentamicin and 
tobramycin), and vancomycin drops, discontinuation of 
these medications may allow for re-epithelialization [3, 
22]. 
The next step in treatment is the application of a 
punctal plug, which will increase retention of 
lubrication, which helps with normal corneal healing as 
tear film contains many growth factors including EGF, 
TGF, TGF-β, basic fibroblast growth factor (bFGF), HGF, 
calcitonin gene-related peptide, fibronectin, and 
vitamins A and C [23]. As discussed, it is important to 
recognize that any toxic medication that the patient is 
prescribed may be retained in the ocular surface with 
this procedure. Additionally, punctal occlusion may 
aggravate the corneal wound in patients with severe 
inflammatory disorders. Silicone or temporary collagen 
plugs are often used [3, 23]. 
Bandage soft contact lenses (BCL) along with 
preservative-free artificial tears and antibiotics are 
beneficial in protecting the damaged epithelium from 
mechanical erosion from eyelid blinking, thus aiding the 
re-epithelialization process. If stromal damage is 
involved, several weeks may be required for corneal 
healing. Lubrication and broad-spectrum topical 
antibiotics should be used concurrently to decrease the 
risk of infectious keratitis [24]. Patients with 
neurotrophic keratitis require consistent monitoring 
due to desensitization and increased risk of the 
progression of infection. Pressure patching is an 
alternative method to protect the cornea during re-
epithelialization; however, pressure patching has been 
shown to impair wound healing and possibly be a 
source of infection, therefore requiring constant 
monitoring every 1-2 days [25]. Thus, pressure patching 
as an alternative to BCL may be less effective compared 
to the other therapies.  
Surgical interventions, such as debridement and 
tarsorrhaphy, are effective in most cases of PED 
refractory to medical management [3]. Debridement is 
the process of removing inert, healing epithelial tissue 
from the edge of the PED to allow for migration of new 
epithelial cells to restore the corneal tissue. The objective 
of a tarsorrhaphy procedure is to keep the palpebral 
fissure closed to decrease the area of exposed cornea. 
The drawstring temporary tarsorrhaphy is particularly 
useful in treating PEDs because it promotes easy access 
to the cornea for examination and medication delivery 
[26]. Temporary suture tarsorrhaphy is an option that 
may sustain the closed palpebral fissure for up to 6 
weeks. Botulinum toxin A can be injected into the levator 
palpebrae superioris muscle to close the eyelids 
nonsurgically [3]. Temporary cyanoacrylate glue with 
patching therapy has been shown to help with the re-
epithelialization process, prevent stromal melting, and 
has bacteriostatic activity [27]. 
Tetracyclines, prophylactic topical antibiotics, and 
steroids are also used as standard therapy for PED. Oral 
tetracyclines exhibit anticollagenolytic activity, inhibiting 
MMPs produced by inflammation mediators, and have 
been shown to be effective in healing PEDs within weeks 
[28]. Prophylactic topical antibiotics may be indicated 
when BCL or invasive procedures are used to prevent 
infection. Topical corticosteroids are controversial in 
treating PED because they may cause tissue destruction, 
stromal melting, and an increased risk of microbial 
keratitis [29]. However, corticosteroids can be very 
effective in treating persistent epithelial defects in 
herpetic keratitis, Stevens-Johnson syndrome, and atopic 
keratoconjunctivitis [5]. Immunosuppression is 
additionally effective in treating PED in Stevens-Johnson 
syndrome, graft vs. host disease, and Sjogren’s syndrome 
[5]. 
Treatment of Refractory Cases 
Refractory cases of PED are those that do not respond to 
the standard therapies discussed above: lubrication, 
bandage soft contact lens, punctal plugs, debridement, 
and tarsorrhaphy.  
Amniotic membranes contain many of the growth factors 
(EGF, KGF, basic fibroblast growth factor [FGF2]), 
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proteinase inhibitors and proteins that facilitate corneal 
wound healing in addition to providing a scaffold for re-
epithelialization, decreasing vascularization, and having 
anti-inflammatory properties [3, 30, 31]. Therefore, 
amniotic membrane grafting or transplant (AMT) has 
proven to be extremely useful for reconstruction of 
surface ocular disorders, such as persistent epithelial 
defects and non-healing corneal ulcerations, to prevent 
corneal perforations [32-34]. Amniotic membranes are 
usually fibrin-glued or sutured underneath a bandage 
soft contact lens [3]. Amniotic membranes have also 
been indicated and used in the treatment of limbal stem 
cell deficiency to promote regeneration of the damaged 
epithelial layer [35, 36]. However, there are a few 
reported complications of AMT including postoperative 
infection, natural-occurring breakage of the sutures, and 
dissolution of the membrane, and hemorrhage beneath 
the amniotic membrane [7, 37] 
Blood serum contains many growth factors, including 
vitamin A, vitamin E, EGF, TGF-β, PDGF, IGF, nerve 
growth factor, substance P, immunoglobulins, and 
fibronectin. Therefore, autologous serum eye drops are 
useful in re-epithelialization when a patient’s serum is 
diluted by 20% or 50% to create the eye drops and used 
every 3 hours daily [38-40] 50% autologous serum eye 
drops have been beneficial in treating severe ocular 
surface disorders, such as a PED [41, 42]. Both the 
combination of silicone-hydrogel soft contact lenses and 
autologous serum eye drops have been particularly 
successful in treating PEDs and preventing corneal 
stromal melting [38, 39, 43, 44]. However, there are a 
few limitations to using autologous serum, including the 
necessity of developing the tears from whole blood and 
associated regulatory restrictions [3]. 
Whole blood-derived products, such as umbilical cord 
blood serum and platelet-rich fibrin tears, can be used 
instead of autologous serum in patients with infection or 
systemic disease [3]. Patients treated with umbilical cord 
blood serum have been shown to have faster healing 
times for re-epithelialization than patients treated with 
platelet-rich fibrin tears [45]. Despite the benefit of 
whole blood-derived products in treating ocular surface 
diseases, these therapies are inconvenient due to the 
risks associated with the transport of whole blood-
derived products, as well as the high supply costs [46]. 
Scleral contact lenses are effective in treating PED due to 
their high oxygen permeability, lubricating properties, 
and protective effects on the corneal epithelium [47]. 
Additionally, a prosthetic replacement of the ocular 
surface ecosystem (PROSE) can be used to promote 
healing overnight [48]. However, one complication of the 
therapies is microbial keratitis, warranting the need for 
prophylactic antibiotics [47, 48]. 
Transplantation of corneal epithelial stem cells can aid in 
re-epithelialization, especially in conditions that damage 
the limbal corneal stem cells, such as in Stevens-Johnson 
syndrome, chemical or thermal burns, or stem cell 
deficiencies [49, 50]. Severe cases of PED, such as 
patients with extensive alkali burns, can be treated with 
penetrating or lamellar keratoplasty if there is a high risk 
for perforation [51]. In patients with multiple failed 
corneal transplantations or grafts, the Boston 
Keratoprosthesis (KPro) implantation may help manage 
corneal LSCDs [52]. Phototherapeutic keratectomy (PTK) 
may be beneficial by applying a laser to the basement 
membrane and Bowman’s layer to facilitate stronger 
adhesion mechanisms [4, 53, 54]. PTK may be able to 
treat both refractive errors and epithelial defects [4]. 
Novel Treatments 
The glycoprotein fibronectin is vital in cellular adhesion in 
the extracellular matrix. Thus, topical fibronectin may be 
helpful for re-epithelialization of a PED [55, 56]. Diabetic 
patients with PEDs experienced successful wound healing 
after topical therapy with fibronectin solution [57]. 
However, the benefit of topical fibronectin is 
controversial in treating persistent epithelial defects, as 
another study showed no significant improvement 
among patients with PEDs who received topical 
fibronectin [58]. 
Thymosin beta 4 (Tβ4) demonstrates efficacy in 
stimulating re-epithelialization processes and 
proliferation of epithelial cells while having anti-
inflammatory effects [3]. The proposed mechanism of 
Tβ4 involves interfering with the synthesis of 
transcription factors mediating inflammation, such as 
nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) and TNF-α [3, 59]. In addition, studies have 
shown the promising ability of Tβ4 as an anti-
inflammatory agent to promote epithelial repair [59]. In a 
study with nine patients with chronic neurotropic PEDs, 
topical Tβ4 was demonstrated as a promising novel 
therapy to treat refractory neurotrophic corneal ulcers 
and epithelial defects [60]. A recently-developed topical 
fibronectin-derived peptide, PHSRN, was shown to 
facilitate wound healing of corneal epithelial defects in 
diabetic rat models [61].  
Nexagon is an antisense oligodeoxynucleotide that 
downregulates connexin43 protein expression [62]. 
Nexagon shows therapeutic potential in treating severe 
ocular burns and epithelial defects with its ability to 
decrease edema and inflammation as well as promote 
cell proliferation [3, 63]. For example, in a prospective 
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study of five eyes with PEDs, Nexagon was able to 
decrease inflammation and complete re-epithelialization 
in all five eyes [63]. 
Therapies in Development 
Epidermal growth factor (EGF) stimulates proliferation of 
limbal and peripheral epithelial cells and stromal 
fibroblasts, promotes the synthesis of fibronectin, and 
serves as a chemotactic agent for both epithelial and 
stromal cells. Thus, EGF enhances the synthesis of 
extracellular matrix proteins to promote epithelial 
healing of corneal injuries [64]. Additionally, corneal 
wound healing is mediated by EGF-induced nuclear 
factor κB p50 and CTCF protein, making both mediators 
important in the growth factor-induced signaling 
pathway [65]. The EGF wound healing pathway also 
involves the activation of phospholipase D (PLD) and the 
downregulation of PAX6 expression [66, 67]. Topical EGF 
has been found to increase the rate of healing in corneal 
epithelial defects by almost twofold within one to two 
days [68, 69]. Another study on rabbit models 
demonstrated that the longer the epidermal growth 
factor is applied to corneal epithelial wounds, the faster 
the rate of epithelial wound healing [70]. In rabbit 
models, when EGF is applied in a controlled-release 
manner, corneal epithelial defects are found to heal 
significantly faster [71]. 
Insulin-like growth factor-1 (IGF-1) facilitates healing of 
PEDs by inducing migration and proliferation of corneal 
epithelial cells. Insulin, present in the tear film, also 
facilitates defect closure by promoting cell proliferation, 
as it is related to IGF-1 [72]. Additionally, IGF-1 stimulates 
expression of IGF receptors in limbal cells, promoting 
limbal stem cell differentiation [73]. Topical IGF-1, when 
applied with substance P, can improve corneal epithelial 
defects in patients with neurotrophic keratopathy by 
stimulating epithelial cell migration, limbal cell 
differentiation, and nerve regeneration in the cornea [7, 
74]. Topical administration of substance-P-derived 
peptide with IGF-1 promoted resurfacing of PEDs within 
four weeks after initiating treatment in stem cell-positive 
patients with neurotrophic keratopathy [75]. Topical 
insulin is also involved in epithelial wound healing, as 0.5 
units per drop four times per day is effective for healing 
postoperative corneal epithelial wounds in diabetic 
patients [76]. Using 1 unit of topical insulin four times a 
day postoperatively has also been shown to induce 
healing of corneal epithelial defects in diabetic patients 
after removal of epithelial tissue during vitreoretinal 
surgery [77]. In diabetic rats, insulin has helped promote 
re-epithelialization after corneal injury; thus, topical 
therapy utilizing insulin administration may be useful in 
treating diabetic keratopathies [78, 79]. 
Human growth hormone (HGH), normally produced by 
the anterior pituitary gland, potentially stimulates 
epithelial cells and fibroblast proliferation through an 
increase in phospho-STAT5 signaling. HGH may also 
stimulate corneal epithelial cell migration by an unknown 
mechanism [7]. However, in a recent study with mouse 
models, HGH has not shown a substantial effect on 
corneal wound healing [80]. 
Albumin eye drops (AED) may be effective in closing 
corneal epithelial defects. Albumin is the major protein 
component in autologous tears, and it, therefore, can be 
beneficial in treating ocular surface diseases such as 
corneal ulcers and epithelial defects [81, 82]. 
Matrix regenerating agent, also known as 
ReGeneraTing Agent (RGTA), includes polymers that 
are analogs to extracellular matrix proteins and act as 
a scaffold. RGTA also provides proteolytic defense for 
epithelial cells as they migrate and proliferate during 
corneal wound healing. Specifically, these analogs 
replace heparan sulfates and bind to collagen, elastin, 
and fibronectin to protect against proteolytic damage 
[83, 84]. In a recent study with twenty-one patients 
with PED, topical RGTA was shown to be effective in 
treating PEDs [85]. RGTA may be useful in managing 
neurotrophic keratopathy as well [84]. In a case study 
involving three patients with neurotrophic PEDs from 
distinct etiologies, RGTA eye drops administered with 
therapeutic contact lenses were beneficial in 
treatment after other conventional therapies were 
unsuccessful [83]. In another case study, three 
patients with PED were effectively treated with RGTA 
applied with BCL, resulting in re-epithelialization 
within 4-21 days [86].  
Amniotic membrane extract eye drops (AMEED) can be 
utilized for tissue healing in severe cases of ocular 
damage. AMEED contains several diverse growth factors 
(EGF, HGF, bFGF, protease inhibitors, and the HC-
HA/PTX3 complex), which supply AMEED with its growth-
promoting and anti-inflammatory properties. Several 
studies have demonstrated the efficacy of AMEED 
therapy to improve ocular surface burns, ulcerations, and 
epithelial damage; therefore, AMEED appears to be a 
promising therapy in treating persistent epithelial defects 
[87]. Additionally, it has shown benefits in promoting 
proliferation of corneal epithelium in vivo and limbal 
stem cells ex vivo and in vivo; thus, AMEED may have 
potential use in treating LSCDs [88, 89].  
Restoration of corneal sensation with corneal 
neurotization, a peripheral sensory nerve graft, is a 
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recent and novel surgical technique to treat neurotrophic 
keratopathy. Corneal neurotization involves transferring 
the contralateral supraorbital and supratrochlear 
ophthalmic branches of the trigeminal nerve to the 
limbal cells of the cornea to re-innervate the corneal 
stroma and sub-basal layers [90, 91]. A recent study 
proposed, after in vivo confocal microscopic and 
histopathological analyses, that regeneration of corneal 
nerves works through a paracrine-mediated mechanism 
[92]. In a case study of six patients without corneal 
sensation, corneal neurotization was effective at 
restoring nerve function [93].  
Oxervate medication, known as Cenegermin-bkbj or 
recombinant human nerve growth factor (rhNGF), has 
recently been FDA approved in the U.S. as a therapy for 
neurotrophic keratitis. Nerve growth factor restores 
sensation and sensitivity of the cornea, induces corneal 
healing, increases tear production, displays 
immunoregulatory effects, and plays a role in sensory 
and sympathetic nerve regeneration post-injury [94]. 
Phase I of the REPARO study determined that 
administering 10 or 20 ug/mL of rhNGF 6 drops per day 
for 8 weeks was well-tolerated and likely had little 
systemic absorption among patients with neurotrophic 
keratitis. Phase II of the study demonstrated in a 
multicenter, randomized, double-masked, and vehicle-
controlled trial that treatment with topical rhNGF was 
not only well tolerated, but also effective in inducing 
corneal healing in patients with moderate-to-severe 
neurotrophic keratitis [95, 96].  
CONCLUSION 
This review summarizes the epidemiology, etiology, 
diagnosis, clinical presentation, and management of 
persistent corneal epithelial defects. Clinicians should be 
aware that without treatment, a PED can cause stromal 
scarring, perforations, secondary infections, ulcerations, 
or even complete vision loss [3, 4]. Although several 
therapies exist, and an increasing number of novel 
approaches are emerging, treatment of PEDs can still be 
quite challenging. Standard treatments, such as BCLs and 
ATs, aim to provide barrier protection to the epithelial 
layer. More recently, medical treatments have been 
developed to target the re-epithelialization process by 
facilitating access to growth factors and anti-
inflammatory agents, as well as new surgical techniques 
that can provide re-innervation to the cornea. Although 
PEDs refractory to treatment are common, newer 
interventions and a stepwise approach to management 
can aid in effectively promoting re-epithelialization in 
these patients. 
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